http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
난치 아토피피부염 전신 치료에 관한 전문가 의견서 업데이트
성명순 ( Myongsoon Sung ),고영일 ( Young-il Koh ),김미애 ( Mi-ae Kim ),김현정 ( Hyunjung Kim ),나정임 ( Jung Im Na ),남동호 ( Dong-ho Nahm ),민택기 ( Taek Ki Min ),박양 ( Yang Park ),이동훈 ( Dong Hun Lee ),이미희 ( Mi-hee Lee ) 대한천식알레르기학회 2024 Allergy Asthma & Respiratory Disease Vol.12 No.2
Atopic dermatitis (AD) is the most prevalent inflammatory skin condition, with approximately 80% of cases originating in childhood and some emerging in adulthood. In South Korea, the estimated prevalence of AD ranges between 10% and 20% in children and 1% and 3% in adults. Severe/recalcitrant AD manifests as a chronic, relapsing skin disorder, persisting with uncontrolled symptoms even after topical steroid treatment. Corticosteroids and systemic immunosuppression, conventionally the standard care for difficult-to-treat diseases, cause numerous undesirable side effects. When AD persists despite topical steroid application, systemic therapies like cyclosporine or systemic steroids become the second treatment strategy. The desire for targeted treatments, along with an enhanced understanding of AD’s pathophysiology, has spurred novel therapeutic development. Recent advances introduce novel systemic options, such as biological agents and small-molecule therapy, tailored to treat severe or recalcitrant AD. Notably, dupilumab, a monoclonal antibody inhibiting interleukin 4 and 13, marked a transformative breakthrough upon gaining approval from the U.S. Food and Drug Administration (FDA) in 2017, leading to a paradigm shift in the systemic treatment of AD. Furthermore, both dupilumab and Janus kinase inhibitors, including baricitinib, abrocitinib, and tofacitinib, now approved by the Korean FDA, have established their applicability in clinical practice. These innovative therapeutic agents have demonstrated favorable clinical outcomes, effectively addressing moderate to severe AD with fewer side reactions than those associated with previous systemic immunosuppressants. This review summarizes the latest advancements and evidence regarding systemic treatments for AD, including newly approved drugs in Korea. (Allergy Asthma Respir Dis 2024;12:58-71)
이화영 ( Hwa Young Lee ),강성윤 ( Sung-yoon Kang ),김경훈 ( Kyunghoon Kim ),김주희 ( Ju Hee Kim ),류광희 ( Gwanghui Ryu ),민진영 ( Jin-young Min ),박경희 ( Kyung Hee Park ),박소영 ( So-young Park ),성명순 ( Myongsoon Sung ),이영수 대한천식알레르기학회 2024 Allergy Asthma & Respiratory Disease Vol.12 No.3
Allergen immunotherapy (AIT) is a causative treatment of allergic diseases in which allergen extracts are regularly administered in a gradually escalated doses, leading to immune tolerance and consequent alleviation of allergic diseases. The need for uniform practice guidelines in AIT is continuously growing as the number of potential candidates for AIT increases and new therapeutic approaches are tried. This updated version of the Korean Academy of Asthma Allergy and Clinical Immunology recommendations for AIT, published in 2010, proposes an expert opinion by specialists in allergy, pediatrics, and otorhinolaryngology. This guideline deals with the basic knowledge of AIT, including mechanisms, clinical efficacy, allergen standardization, important allergens in Korea, and special consideration in pediatrics. The article also covers the methodological aspects of AIT, including patient selection, allergen selection, schedule and doses, follow-up care, efficacy measurements, and management of adverse reactions. Although this guideline suggests the optimal dosing schedule, an individualized approach and modifications are recommended considering the situation for each patient and clinic.
김민지 ( Minji Kim ),김현희 ( Hyun Hee Kim ),김효빈 ( Hyo-bin Kim ),나영호 ( Yeong-ho Rha ),박양 ( Yang Park ),성명순 ( Myongsoon Sung ),신윤호 ( Youn Ho Shin ),염혜영 ( Hye Yung Yum ),이경석 ( Kyung Suk Lee ),이용주 ( Yong Ju Le 대한천식알레르기학회 2021 Allergy Asthma & Respiratory Disease Vol.9 No.4
Allergic rhinitis (AR) is one of the most common allergic diseases characterized by stuffy nose, rhinorrhea, sneezing, and itching. Re-searchers have indicated an increase in the prevalence of AR and younger-age onset during the last few decades. The increasing burden of AR has caused many researchers to investigate time trends of the prevalence of AR and to identify its risk factors. The most commonly used epidemiological studies are cross-sectional ones such as the International Study of Asthma and Allergies in Childhood study and big data from National Health Insurance Service or National Health and Nutrition Examination Survey. How-ever, these studies have many limitations including recall bias, selection bias, and deficit of objective evaluation. Furthermore, cross- sectional studies cannot reflect new risk factors associated with the development of AR. New epidemiological studies will be needed to cover genetic factors, environmental changes, microbiomes, and lifestyles that are known to be risk factors for AR. Fur-ther studies will be needed to determine the prevalence, natural history, and risk factors of AR in order to advance our understand-ing of the pathophysiology, prevention, and management of comorbidities of AR. (Allergy Asthma Respir Dis 2021;9:203-207)
전윤홍 ( Yoon Hong Chun ),김민지 ( Minji Kim ),김효빈 ( Hyo-bin Kim ),나영호 ( Yeong-ho Rha ),박양 ( Yang Park ),박용민 ( Yong Mean Park ),성명순 ( Myongsoon Sung ),신윤호 ( Youn Ho Shin ),염혜영 ( Hye Yung Yum ),이경석 ( Kyung S 대한천식알레르기학회 2022 Allergy Asthma & Respiratory Disease Vol.10 No.2
Among allergic diseases of the Korean pediatric population, allergic rhinitis shows the most rapidly increasing prevalence. Its economic burden is substantial in many Asian countries including South Korea. This investigation of its risk factors aims to reduce the socioeconomic burden by blocking exposure of susceptible individuals to identified causes. However, the risk factors of allergic rhinitis varied considerably depending on the seasons, geographical locations, and populations involved. This review article primarily deals with studies on the risk factors for allergic rhinitis in Korean children that were published during the last 10 years and additionally investigates associated large scale international studies. Our investigation identified several single-nucleotide polymorphisms, inhalant allergens, pollution, tobacco smoke, chemicals, and family affluence as risk factors for allergic rhinitis. In contrast, breastfeeding, older sibling, and microbial diversity were protective factors against allergic rhinitis. This suggests that various genetic and environmental factors might affect the manifestation and presentation of allergic rhinitis complexly. These findings are beneficial as they can provide insights into modifiable risk factors that may hinder the development of allergic rhinitis. (Allergy Asthma Respir Dis 2022;10:73-79)